Pfizer (NYSE:PFE) Stock Price Down 1.9% – What’s Next?

Pfizer Inc. (NYSE:PFE) shares traded down 1.9% during mid-day trading on Friday . The stock traded as low as $24.51 and last traded at $24.5250. 28,498,154 shares were traded during trading, a decline of 33% from the average daily volume of 42,257,414 shares. The stock had previously closed at $25.01.

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. HSBC cut Pfizer from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. Citigroup raised their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Finally, UBS Group reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $28.50.

Pfizer Stock Performance

The firm has a market capitalization of $139.78 billion, a P/E ratio of 18.72 and a beta of 0.35. The firm has a 50-day moving average price of $25.13 and a two-hundred day moving average price of $26.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the prior year, the business posted $0.92 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PFE. Vermillion Wealth Management Inc. lifted its holdings in shares of Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 382 shares during the period. Triad Wealth Partners LLC lifted its stake in Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 386 shares during the period. Eagle Capital Management LLC lifted its stake in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after acquiring an additional 390 shares during the period. ETF Store Inc. boosted its position in Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after acquiring an additional 396 shares in the last quarter. Finally, Delta Financial Advisors LLC increased its holdings in shares of Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 398 shares during the period. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.